Cabozantinib in monotherapy and combination therapy for first-line renal cell carcinoma: Patient profiles Review article
Article Sidebar
Main Article Content
Abstract
Systemic treatment of metastatic kidney cancer is continuously evolving, which leads to the need to choose between monotherapy with tyrosine kinase inhibitors or the use of one of the dual therapy regimens.
Cabozantinib, a tyrosine kinase inhibitor of VEGFR, MET, and AXL receptors, is registered for monotherapy and in combination with nivolumab as a first-line treatment for patients with metastatic kidney cancer. The drug is characterized by a good profile of efficacy and side effects, as demonstrated in both clinical trials and the results of real-world data analyses. Cabozantinib also has specific pharmacokinetic features, which may be a consideration when choosing treatment. Cabozantinib represents a valuable treatment option in the first line for patients with metastatic kidney cancer and a defined clinical profile.
Downloads
Article Details
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. Motzer RJ, Hutson TE, Tomczak P. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009; 27: 3584-90.
3. Motzer RJ, Hutson TE, Cella D. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013; 369: 722-31.
4. Sternberg CV, Davis ID, Mardiak J. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010; 28: 1061-8.
5. Choueiri TK, Hassel C, Halabi S. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate and poor risk: Progression-free survival by independent review and overall survival update. Eur J Cancer. 2018; 94: 115-25.
6. Lyseng-Williamson KA. Cabozantinib as first line treatment in advanced renal cell carcinoma: a profile of its use. Drug&Ther Prosp. 2018; 34: 457-65.
7. Kucharz J, Poprach A, Sikora-Kupis B. Cabozantinib in the First-Line Treatment of Patients with Metastatic Renal Cell Carcinoma, Real-World Data from the Czech Republic and Poland: ICARO-RC Project. Clin Genitourin Cancer. 2025; 23(4): 102382.
8. Manz KM, Fenchel K, Eilers A. Efficacy and safety of approved first-line tyrosine kinase inhibitor treatments in metastatic renal cell carcinoma: a network meta-analysis. Adv Ther. 2020; 37: 730-44.
9. Albiges L, Flechon A, Chverau CG. Real World evidence of cabozantinib in patients with metastatic renal cell carcinoma: Results from the CABOREAL Early Avcess Program. Eur Jour Canc. 2021; 142: 101-11.
10. Choueiri TK, Powles T, Burotto M. Nivolumab plus cabozantinib versus sunininib for advanced renal-cell carcinoma. N Engl J Med. 2021; 384(9): 829-41.
11. Cella DM, Motzer RJ, Suarez C. Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patient with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomized, phase 3 trial. Lancet Oncol. 2022; 23: 292-303.
12. Brown J, Santini D, Charnley N. Implications of bone metastasis on response to systemic therapy in patients with advanced renal cell carcinoma: A systemic literature review. Canc Treat Rev. 2024; 129: 1-10.
13. Choy E, Cote GM, Dror Michaelson M. Phase II study of Cabozantinib in patients with bone metastasis. Oncologist. 2022; 27: 600-6.
14. Nakagawa T, Kijima T, Imasato N. Efficacy of cabozantinib for brain metastasis from renal cell carcinoma. Int Jour Urol. 2022; 5: 293-6.
15. Negrier S, Mourey L, Blanc M et al. Cabozantinib in patients with non-locally pretreated brain metastases from renal cell carcinoma: Results of the multicenter CABRAMET phase II trial (NCT03967522). J Clin Oncol. 2025; 43(suppl 5): abstr 533.
16. Iaxx R, Lefort F, Domblide Ch. An evaluation of cabozantinib for the treatment of rena cell carcinoma: focus on patient selection and perspectives. Ther Clin Risk Man. 2022; 18: 619-22.
17. Schmidinger M, Danesi R. Management of adverse events associated with cabozantinib therapynin renall cell carcinoma. Oncologist. 2018; 23: 306-15.
18. Flechon A, Chevereau CM, Topart DM. Cabozantinib in non-clear metastaic renal cell carcinoma and sarcomatoid renal cell carcinoma: real world data from the CABOREAL study. Ann Oncol. 2020; 31: 572-3.
19. Pal SK, Tangen C, Thompson IM Jr et al. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial. Lancet. 2021; 397(10275): 695-703.